

# Nicholas A. Kennedy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9273026/publications.pdf>

Version: 2024-02-01

116  
papers

8,680  
citations

76326

40  
h-index

49909

87  
g-index

122  
all docs

122  
docs citations

122  
times ranked

12545  
citing authors

#	ARTICLE	IF	CITATIONS
1	Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity. <i>Gut</i> , 2023, 72, 410-412.	12.1	5
2	Patient-led Remote IntraCapillary pharmacokinetic Sampling (fingerPRICKS) for Therapeutic Drug Monitoring in patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 190-198.	1.3	7
3	Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2022, 21, 102927.	5.8	132
4	Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 591-600.	1.3	23
5	Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 389-397.	1.3	39
6	Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000763.	2.7	4
7	Establishment of a validated central reading system for ileocolonoscopy in an academic setting. <i>Gut</i> , 2022, 71, 661-664.	12.1	3
8	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 342-352.	8.1	100
9	Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis. <i>Gastrointestinal Nursing</i> , 2022, 20, 34-41.	0.1	0
10	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. <i>Nature Communications</i> , 2022, 13, 1379.	12.8	48
11	Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. <i>Gut</i> , 2022, 71, 1426-1439.	12.1	20
12	Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. <i>Lancet Rheumatology</i> , The, 2022, 4, e490-e506.	3.9	61
13	Understanding anti-TNF treatment failure: does serum triiodothyronine/thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 783-793.	3.7	5
14	Incidence and prevalence of inflammatory bowel disease in Devon, UK. <i>Frontline Gastroenterology</i> , 2021, 12, 461-470.	1.8	18
15	Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 699-708.	1.3	36
16	The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn's Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 800-812.	1.3	22
17	P92...Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multi-centre UK experience. , 2021, , .		0
18	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. <i>Gut</i> , 2021, 70, 865-875.	12.1	153

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 218-224.	8.1	111
20	Integrating a treat to target approach into clinical practice in 2020. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 6-7.	2.8	0
21	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. <i>Gut</i> , 2021, 70, 1884-1893.	12.1	233
22	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 271-281.	8.1	23
23	P401 Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S409-S410.	1.3	0
24	P387 Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S398-S399.	1.3	0
25	Response to "Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis". <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1775-1776.	1.3	0
26	SARS-CoV-2 vaccination for patients with inflammatory bowel disease " Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 523-524.	8.1	2
27	Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 999-1012.	3.7	7
28	Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 128-137.	3.7	9
29	Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2021, 82, 1-11.	0.5	0
30	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. <i>Nature Genetics</i> , 2021, 53, 1543-1552.	21.4	96
31	OFR-8...Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. , 2021, , .		2
32	Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 291-301.	3.7	5
33	Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1236-1240.	3.7	5
34	GWAS of stool frequency provides insights into gastrointestinal motility and irritable bowel syndrome. <i>Cell Genomics</i> , 2021, 1, 100069.	6.5	15
35	Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications"reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1236-1240.	3.7	7
36	Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 291-301.	3.7	19

#	ARTICLE	IF	CITATIONS
37	Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease—getting to the root. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 337-338.	3.7	1
38	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 526.	4.4	0
39	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2020, 158, 189-199.	1.3	249
40	Immunomodulator and Biologic Combination Therapy in IBD: The Debate That Just Won't Go Away?. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1343-1344.	1.3	2
41	Letter: online search trends suggest patient concerns around immunosuppression use in inflammatory bowel disease during COVID-19 in the United Kingdom. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 937-939.	3.7	2
42	Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic. <i>Frontline Gastroenterology</i> , 2020, 11, 343-350.	1.8	37
43	Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. <i>Archives of Disease in Childhood</i> , 2020, 105, 957-963.	1.9	4
44	Quality improvement project identifies factors associated with delay in IBD diagnosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 471-480.	3.7	14
45	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. <i>Gut</i> , 2020, 69, gutjnl-2020-321927.	12.1	28
46	Whole Blood Profiling of T-cell-Derived microRNA Allows the Development of Prognostic models in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1724-1733.	1.3	16
47	Practice pattern variability in the management of acute severe colitis: a UK provider survey. <i>Frontline Gastroenterology</i> , 2020, 11, 272-279.	1.8	6
48	Massively parallel variant characterization identifies <i>NUDT15</i> alleles associated with thiopurine toxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 5394-5401.	7.1	95
49	DOP69 Tofacitinib in ulcerative colitis: Early 'real-world' experience from four UK tertiary centres. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S106-S106.	1.3	0
50	Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1385-1393.	1.3	74
51	DOP28 Understanding the molecular mechanisms of anti-TNF treatment failure in patients with Crohn's disease: A pilot serum proteomic analysis of the PANTS cohort. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S067-S068.	1.3	3
52	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. <i>Gut</i> , 2020, 69, 984-990.	12.1	232
53	Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2269-2276.e4.	4.4	48
54	Editorial: accelerated infliximab induction—it's time to settle the debate! Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1061-1062.	3.7	0

#	ARTICLE	IF	CITATIONS
55	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. <i>Gut</i> , 2019, 68, s1-s106.	12.1	1,353
56	Predictors of anti-TNF treatment failure in anti-TNF-naïve patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 341-353.	8.1	431
57	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 773.	7.4	129
58	PWE-010â€¦Introduction of a primary care dietetics service for functional gut disorders. , 2019, , .		0
59	Faecal Calprotectin and Magnetic Resonance Enterography in Ileal Crohn's Disease: Correlations Between Disease Activity and Long-Term Follow-Up. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 442-450.	1.3	20
60	The Impact of NOD2 Variants on Fecal Microbiota in Crohn's Disease and Controls Without Gastrointestinal Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 583-592.	1.9	40
61	Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1103-1116.	3.7	31
62	Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018, 154, 1320-1333.e10.	1.3	116
63	OP013 HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S009-S010.	1.3	9
64	MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation. <i>Mucosal Immunology</i> , 2018, 11, 120-130.	6.0	70
65	Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018, 155, 829-843.	1.3	80
66	Promoter methylation of the <i>MGAT3</i> and <i>BACH2</i> genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease. <i>Clinical Epigenetics</i> , 2018, 10, 75.	4.1	32
67	Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 256-261.	21.4	943
68	Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at <i>ADCY7</i> . <i>Nature Genetics</i> , 2017, 49, 186-192.	21.4	153
69	Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 660-669.	3.7	96
70	Editorial: which iron preparation for patients with IBD?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 194-195.	3.7	6
71	A plea for TDM-based optimisation for treatment of Crohn's disease â€“ Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 81-82.	8.1	0
72	Interaction Between NOD2 and Smoking in the Pathogenesis of Crohn's Disease. <i>EBioMedicine</i> , 2017, 21, 49-50.	6.1	2

#	ARTICLE	IF	CITATIONS
73	A randomised, double-blind, parallel-group trial to assess mercaptopurine versus placebo to prevent or delay recurrence of Crohn's disease following surgical resection (TOPPIC). Efficacy and Mechanism Evaluation, 2017, 4, 1-60.	0.7	4
74	Colonoscopy quality with Entonox <sup>®</sup> vs intravenous conscious sedation: 18608 colonoscopy retrospective study. World Journal of Gastrointestinal Endoscopy, 2017, 9, 471.	1.2	10
75	Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases. American Journal of Gastroenterology, 2016, 111, 1796-1805.	0.4	88
76	Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2016, 1, 273-282.	8.1	91
77	Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease. Nature Communications, 2016, 7, 13507.	12.8	191
78	DNA methylation in a Scottish family multiply affected by bipolar disorder and major depressive disorder. Clinical Epigenetics, 2016, 8, 5.	4.1	23
79	Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Alimentary Pharmacology and Therapeutics, 2016, 43, 910-923.	3.7	87
80	Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet, The, 2016, 387, 156-167.	13.7	607
81	Common polygenic variation in coeliac disease and confirmation of ZNF335 and NIFA as disease susceptibility loci. European Journal of Human Genetics, 2016, 24, 291-297.	2.8	25
82	Inflammatory Bowel Disease Associates with Proinflammatory Potential of the Immunoglobulin G Glycome. Inflammatory Bowel Diseases, 2015, 21, 1.	1.9	161
83	Predicting outcomes in acute severe ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2015, 9, 405-415.	3.0	12
84	Serum C-reactive Protein and CRP Genotype in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 596-605.	1.9	38
85	Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology, 2015, 149, 1716-1730.	1.3	180
86	MicroRNAs: new players in IBD. Gut, 2015, 64, 504-513.	12.1	223
87	Changes to Serum Sample Tube and Processing Methodology Does Not Cause Inter-Individual Variation in Automated Whole Serum N-Glycan Profiling in Health and Disease. PLoS ONE, 2015, 10, e0123028.	2.5	15
88	The Impact of Different DNA Extraction Kits and Laboratories upon the Assessment of Human Gut Microbiota Composition by 16S rRNA Gene Sequencing. PLoS ONE, 2014, 9, e88982.	2.5	236
89	Comparison of mortality following hospitalisation for ulcerative colitis in Scotland between 1998-2000 and 2007-2009. Alimentary Pharmacology and Therapeutics, 2014, 39, 1387-1397.	3.7	13
90	Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Alimentary Pharmacology and Therapeutics, 2014, 40, 1313-1323.	3.7	55

#	ARTICLE	IF	CITATIONS
91	Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50years. <i>Journal of Crohn's and Colitis</i> , 2014, 9, 41-9.	1.3	43
92	Letter: faecal calprotectin and lactoferrin – accurate biomarkers in post-operative Crohn's disease – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 323-323.	3.7	1
93	Letter: azathioprine-induced pancreatitis and subsequent tolerance of mercaptopurine – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 440-441.	3.7	2
94	Two-stage Genome-wide Methylation Profiling in Childhood-onset Crohn's Disease Implicates Epigenetic Alterations at the VMP1/MIR21 and HLA Loci. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1784-1793.	1.9	84
95	Systematic review: the use of thiopurines or anti-TNF in post-operative Crohn's disease maintenance – progress and prospects. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1253-1265.	3.7	43
96	Editorial: early corticosteroids in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 727-727.	3.7	2
97	Dietary Manipulation of Oncogenic MicroRNA Expression in Human Rectal Mucosa: A Randomized Trial. <i>Cancer Prevention Research</i> , 2014, 7, 786-795.	1.5	94
98	The role of glycosylation in IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 588-600.	17.8	123
99	Beyond Gene Discovery in Inflammatory Bowel Disease: The Emerging Role of Epigenetics. <i>Gastroenterology</i> , 2013, 145, 293-308.	1.3	275
100	PWE-108...Assessment of the Mucosal Microbiota in Inflammatory Bowel Disease. <i>Gut</i> , 2013, 62, A174.2-A175.	12.1	0
101	Optimisation of hepatocellular carcinoma surveillance in patients with viral hepatitis: a quality improvement study. <i>Internal Medicine Journal</i> , 2013, 43, 772-777.	0.8	26
102	Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease. <i>Internal Medicine Journal</i> , 2013, 43, 278-286.	0.8	25
103	A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1255-1266.	3.7	54
104	PTH-079...Thiopurine Withdrawal for Sustained Remission in IBD: A UK Multicentre Study. <i>Gut</i> , 2013, 62, A243.1-A243.	12.1	0
105	PTH-082...Serum Calprotectin: A Novel Biomarker to Predict Outcome in Acute Severe Ulcerative Colitis?. <i>Gut</i> , 2013, 62, A244.2-A245.	12.1	3
106	PTU-123...Acute severe ulcerative colitis: the last 12 years in Edinburgh: Abstract PTU-123 Figure 1. <i>Gut</i> , 2012, 61, A235.2-A236.	12.1	1
107	The Diagnostic Accuracy of Fecal Calprotectin During the Investigation of Suspected Pediatric Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2012, 107, 941-949.	0.4	94
108	OC-166...Predictive factors of disease relapse following thiopurine withdrawal for sustained clinical remission of IBD: Abstract OC-166 Figure 1. <i>Gut</i> , 2012, 61, A71.2-A72.	12.1	0



#	ARTICLE	IF	CITATIONS
109	Genome-wide methylation profiling in Crohn's disease identifies altered epigenetic regulation of key host defense mechanisms including the Th17 pathway. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 889-899.	1.9	152
110	Nationwide linkage analysis in Scotland to assess mortality following hospital admission for Crohn's disease: 1998-2000. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 142-153.	3.7	15
111	Mortality in patients hospitalised with Crohn's disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 397-398.	3.7	0
112	A guide to out of programme training and experience in Australia. <i>British Journal of Hospital Medicine</i> (London, England: 2005), 2011, 72, M141-M144.	0.5	0
113	Exploring the hidden heritability of inflammatory bowel disease. <i>Gut</i> , 2011, 60, 1447-1448.	12.1	6
114	Atypical paraneoplastic pemphigus secondary to endometrial carcinoma with no mucosal involvement. <i>Clinical and Experimental Dermatology</i> , 2009, 34, e130-e133.	1.3	7
115	The UK IBD Registry COVID-19 Risk Tool; Patient Generated Data Can Improve the Hospital Record. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
116	A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data Report. <i>Wellcome Open Research</i> , 0, 6, 360.	1.8	8